Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New eczema drug shows promise in Long-Term safety check

NCT ID NCT05916365

Completed Disease control Sponsor: Almirall, S.A. Source: ClinicalTrials.gov ↗

First seen May 14, 2026 · Last updated May 19, 2026 · Updated 1 time

Summary

This study looked at the long-term safety and effectiveness of lebrikizumab for adults and teens with moderate-to-severe atopic dermatitis (eczema). Participants who had already completed a previous study were given lebrikizumab for up to 2 more years. The goal was to see how many people stopped treatment due to side effects and how well the drug controlled their eczema symptoms.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Investigator Site 1

    Augsburg, 86150, Germany

  • Investigator Site 10

    Bad Bentheim, Lower Saxony, 48455, Germany

  • Investigator Site 11

    Münster, North Rhine-Westphalia, 48149, Germany

  • Investigator Site 12

    Leipzig, Saxony, 04103, Germany

  • Investigator Site 13

    Gdansk, 80-462, Poland

  • Investigator Site 14

    Katowice, 40-600, Poland

  • Investigator Site 15

    Kielce, 25-155, Poland

  • Investigator Site 16

    Lublin, 20-081, Poland

  • Investigator Site 17

    Poznan, 60-214, Poland

  • Investigator Site 18

    Rzeszów, 35-055, Poland

  • Investigator Site 19

    Szczecin, 71-434, Poland

  • Investigator Site 2

    Berlin, 10789, Germany

  • Investigator Site 20

    Tarnów, 33-100, Poland

  • Investigator Site 21

    Warsaw, 01-142, Poland

  • Investigator Site 22

    Wroclaw, 50-566, Poland

  • Investigator Site 23

    Wroclaw, Lower Silesian Voivodeship, 51-503, Poland

  • Investigator Site 24

    Lodz, Łódź Voivodeship, 90-436, Poland

  • Investigator Site 25

    Krakow, Lesser Poland Voivodeship, 31-559, Poland

  • Investigator Site 26

    Krakow, Lesser Poland Voivodeship, 30-033, Poland

  • Investigator Site 27

    Warsaw, Masovian Voivodeship, 02-625, Poland

  • Investigator Site 28

    Warsaw, Masovian Voivodeship, 02-507, Poland

  • Investigator Site 29

    Ossy, Silesian Voivodeship, 42-624, Poland

  • Investigator Site 3

    Berlin, 13055, Germany

  • Investigator Site 30

    Gdansk, Woj. Pomorskie, 80-344, Poland

  • Investigator Site 31

    Iwonicz-Zdrój, Podkarpackie Voivodeship, 38-440, Poland

  • Investigator Site 32

    Katowice, Silesian Voivodeship, 40-611, Poland

  • Investigator Site 4

    Dresden, D-01307, Germany

  • Investigator Site 5

    Hamburg, 20144, Germany

  • Investigator Site 6

    Hamburg, 20537, Germany

  • Investigator Site 7

    Darmstadt, Hesse, 64283, Germany

  • Investigator Site 8

    Frankfurt am Main, Hesse, 60590, Germany

  • Investigator Site 9

    Osnabrück, Lower Saxony, 49074, Germany

Conditions

Explore the condition pages connected to this study.

ATOPIC DERMATITIS